{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:36:02Z","timestamp":1761708962528},"reference-count":54,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T00:00:00Z","timestamp":1399593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>) is a <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> cell\u2010derived lymphoid malignancy most often affecting young adults. More than 80% of <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> patients achieve long\u2010term remission after appropriate first\u2010line treatment consisting of multiagent chemotherapy and\/or radiotherapy (<jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>). In addition, approximately 50% of patients with disease recurrence remain relapse\u2010free after salvage therapy with high\u2010dose chemotherapy followed by autologous stem cell transplantation (<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>). However, patients with multiple relapses are mostly in a palliative situation, and novel drugs for this patient group are needed. Furthermore, novel less toxic but equally effective first\u2010line and second\u2010line approaches are required as therapy\u2010related late sequelae represent a relevant cause of morbidity and mortality in <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> survivors. Several antibodies and antibody\u2010drug conjugates (<jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content>) targeting <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>30 and <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 have recently been evaluated in <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>. Excellent response rates in heavily pretreated patients were observed with the <jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content> brentuximab vedotin directed against <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>30. Thus, ongoing trials investigate brentuximab vedotin in different additional indications. One example is the first\u2010line treatment of advanced <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> where the drug is currently being evaluated in combination with variants of the first\u2010line protocols <jats:styled-content style=\"fixed-case\">ABVD<\/jats:styled-content> (adriamycin, bleomycin, vinblastine, dacarbazine) and escalated <jats:styled-content style=\"fixed-case\">BEACOPP<\/jats:styled-content> (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). Anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 antibodies given either as single agent or in combination with conventional chemotherapy have also been investigated and still undergo investigation in prospective studies including <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> patients. This article reviews the available data on treatment approaches including antibodies and <jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> patients.<\/jats:p>","DOI":"10.1111\/ejh.12347","type":"journal-article","created":{"date-parts":[[2014,4,21]],"date-time":"2014-04-21T15:55:52Z","timestamp":1398095752000},"page":"1-8","source":"Crossref","is-referenced-by-count":10,"title":["Antibodies and antibody\u2010drug conjugates in the treatment of <scp>H<\/scp>odgkin lymphoma"],"prefix":"10.1111","volume":"93","author":[{"given":"Dennis A.","family":"Eichenauer","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine University Hospital Cologne Cologne Germany"},{"name":"German Hodgkin Study Group (GHSG) Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine University Hospital Cologne Cologne Germany"},{"name":"German Hodgkin Study Group (GHSG) Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,9]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr378"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.266"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8869"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.91"},{"key":"e_1_2_5_6_1","article-title":"Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant","author":"Tresckow B","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt206"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.798868"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1006\/smim.1998.0156"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"e_1_2_5_11_1","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1182\/blood.V122.21.4344.4344","article-title":"Targeted beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin Lymphoma: interim results of a randomized phase II Study","volume":"122","author":"Borchmann P","year":"2013","journal-title":"Blood"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-078725"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-361055"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.2069"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/299065a0"},{"key":"e_1_2_5_16_1","first-page":"3736","article-title":"The anti\u2010CD30 monoclonal antibody SGN\u201030 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease","volume":"62","author":"Wahl AF","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403884"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099317"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07740.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq211"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0515"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8972"},{"key":"e_1_2_5_23_1","first-page":"1227","article-title":"Abstract #1227: A phase I, open\u2010label, dose\u2010escalation, multidose study of MDX\u20101401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30\u2010positive refractory\/relapsed Hodgkins lymphoma","volume":"2009","author":"Thertulien R","year":"2009","journal-title":"AACR Meeting Abst"},{"issue":"15","key":"e_1_2_5_24_1","first-page":"8531","article-title":"Phase I study of an anti\u2010CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy","volume":"27","author":"Blum KA","year":"2009","journal-title":"ASCO Meeting Abst"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2042"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0295"},{"key":"e_1_2_5_27_1","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1182\/blood.V122.21.5116.5116","article-title":"A phase I study of an Anti\u2010CD30 x Anti\u2010CD16A bispecific tandab antibody, AFM13, in patients with relapsed or refractory Hodgkin lymphoma","volume":"122","author":"Rothe A","year":"2013","journal-title":"Blood"},{"key":"e_1_2_5_28_1","first-page":"1779","article-title":"A Phase I study with an anti\u2010CD30 ricin A\u2010chain immunotoxin (Ki\u20104.dgA) in patients with refractory CD30+ Hodgkin's and non\u2010Hodgkin's lymphoma","volume":"8","author":"Schnell R","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07963.x"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1350"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21664"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-430918"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.069393"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0133"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.775434"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-418673"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-397893"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.876496"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-24"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11511"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23237"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-402792"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405456"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi323"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.0945"},{"key":"e_1_2_5_49_1","first-page":"2812","article-title":"Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) patients treated with R\u2010CHOP","volume":"116","author":"Fanale MA","year":"2010","journal-title":"ASH Ann Meeting Abst"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.03.008"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.3721"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034405"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8268"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-512657"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.550"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12347","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:21:42Z","timestamp":1695514902000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,9]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/ejh.12347"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12347","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,9]]}}}